ArticleHepatology international2026
Dual elastography ultrasound for classifying metabolic dysfunction-associated steatotic liver disease: a cross-sectional study within a prospective cohort.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundThe binary diagnostic approach does not reflect the entire spectrum of metabolic dysfunction associated steatotic liver disease (MASLD. We used an elastography technology, dual elastography ultrasound (DEUS), to discriminate the different stages of MASLD.
methodThis prospective multicenter study was conducted from December 2020 to March 2022. All patients underwent DEUS scan, a liver biopsy, and a liver function laboratory test. The optimal model was developed (Model
resultsThe study included 312 patients in the derivation cohort and 135 in the validation cohort (7:3). Combining DEUS and clinical parameters, a ternary classification of MASLD in the validation cohort achieved a macro-average AUC of 0.858 (95% CI: 0.793, 0.925). The AUC for the diagnosis of MASH with ≥ F3 fibrosis of Model
conclusionMulticenter data analysis demonstrated DEUS' advanced ability in continuous stratification of MASLD, which will provide a low-cost, easily accessible, and accurate noninvasive tools (NIT) for MASLD.
Indexed as
Identifiers
41642476What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.